This month in biotech, “Some of the industry’s biggest players are waiting for clinical trial results and decisions from the FDA that could send their stock prices rocketing higher overnight or stomp them into the dirt,” notes the author of today’s article. He proceeds to examine three biotech stocks in this situation – and offers his take on what’s in store for them. For more, CLICK HERE.
Reading The Tea Leaves On Some Major Biotech Catalysts This Month
- by RobH